Actively Recruiting

Phase 2
Age: 1Year - 19Years
All Genders
NCT03214354

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Led by University of Calgary · Updated on 2026-05-01

12

Participants Needed

1

Research Sites

573 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.

CONDITIONS

Official Title

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Who Can Participate

Age: 1Year - 19Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients must be 1 year or older and younger than 19 years at enrollment
  • Diagnosis of sickle cell disease confirmed by hemoglobin electrophoresis, including HbSS, HbSC, HbS/beta-plus-thalassemia, or HbS/beta-zero-thalassemia
  • Patients must meet standard criteria for stem cell transplant including one or more of the following: multiple vaso-occlusive crises, history of stroke, elevated transcranial Doppler velocity not eligible for hydroxyurea, acute chest syndrome, splenic sequestration crisis, priapism in males, osteonecrosis, pulmonary hypertension, or red cell allo-immunization
  • Sickle cell complications may be present despite hydroxyurea use or if the patient is considered high risk for further crises by their doctor
Not Eligible

You will not qualify if you...

  • Inability to comply with or follow the study protocol
  • Known allergy or hypersensitivity to sirolimus or its components

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Alberta Children's Hospital

Calgary, Alberta, Canada, T3B 6A8

Actively Recruiting

Loading map...

Research Team

T

Tony Truong, MD, MPH

CONTACT

G

Greg Guilcher, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here